Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
•
Male and Female Reproductive Disorders
•
Primary Care
Do you regularly counsel younger women of childbearing age about the impact of Tirzepatide on oral hormonal contraception?
https://pubmed.ncbi.nlm.nih.gov/37940101/
Related Questions
What is your approach to patients with persistent low libido despite normal testosterone levels after use of exogenous testosterone replacement therapy?
After what time frame off GLP-1 RA therapy should you restart at the lowest starting dose?
What is the typical timeline for remission of autoimmune hypoglycemia?
How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?
How do you counsel patients on the use of compounded weight loss medications?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Is GLP-1 therapy a viable treatment option for a patient with Type 2 Diabetes complicated by atherosclerotic heart disease and cholelithiasis?
Can a patient with a PMHx of pancreatic injury or disease (i.e. blunt trauma, recurrent pancreatitis) take a GLP-1 agonist safely in the setting of morbid obesity and type 2 diabetes?
Can clomiphene therapy cause low libido while increasing the testosterone level in men with low testosterone?
How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?